Pathways and interactions accounting for the oligomerization of amyloid peptides
Pathways and interactions accounting for the oligomerization of amyloid peptides
批准号:
10804128
负责人:
Cristiano Luis Dias
金额:
$6.38万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-09-22 至 2025-08-31
关键词:
AccountingAddressAffectAlzheimer&aposs DiseaseAmino Acid SequenceAmyloidAmyloid FibrilsAmyloid ProteinsAmyloid beta-ProteinAmyloidosisBindingBiochemicalBiophysicsBrainCell membraneChemistryComparative StudyComplementComputer SimulationComputersDevelopmentDiseaseDrug DesignEventFDA approvedGoalsGroup MeetingsIndividualKineticsKnowledgeLengthLightLipidsMembrane LipidsMethodsMutateNeurodegenerative DisordersNeurofibrillary TanglesParkinson DiseasePathway interactionsPatientsPeptidesPerformancePharmaceutical PreparationsPositioning AttributePreventive treatmentProcessResearchResearch Project GrantsRunningSenile PlaquesSolventsSurfaceTestingTimeToxic effectTranslatingUniversitiesabeta oligomeramyloid peptidebiophysical chemistrycostexperimental studyimprovedinnovationinsightinterestmolecular dynamicsmonomerpeptide Apreventprotein aminoacid sequencerational designsimulationsupercomputertau Proteinstemporal measurementundergraduate student
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The aggregation of amyloid peptides into soluble oligomers and fibrils is a hallmark of Alzheimer’s
disease. The interaction of these aggregates with the cell membrane accounts for an important
mechanism of toxicity wherein oligomers can form pores in lipid membranes and amyloid fibrils can
induce lipid loss. As monomers, i.e., individual peptides, have been found to be mostly nontoxic, the
development of strategies to inhibit aggregation has the potential to translate into the development of
new preventive treatments for Alzheimer’s disease. These efforts require, however, a deep
understanding of the interactions accounting for amyloid aggregation.
Previously, the aggregation of peptides in bulk solution, i.e., primary nucleation, was assumed to be
the main mechanism accounting for the formation of oligomers. More recently, this assumption was
reassessed by careful kinetic experiments, which can only be explained quantitatively assuming that
most oligomers form on the surface of existing fibrils in a process known as secondary nucleation.
Currently, there is a critical lack of understanding of the molecular interactions and pathways accounting
for secondary nucleation. This remains a serious impediment for the rational design of drugs that can
inhibit oligomerization on the fibril surface. This proposal uses innovative all-atom molecular dynamics
simulations complemented with biophysical and biochemical experiments to fill this knowledge gap. It
takes advantage of improvements in the development of force fields as well as in the enhanced
performance of today’s supercomputers that can now track the position of many atoms (~250,000
atoms) for a long-time (>10 μs). Moreover, this project provides opportunities for undergraduate
students to participate in all aspects of this research including setting up, running, and analyzing
simulations in different supercomputer clusters.
All-atom simulations will be used in aim 1 of this project to determine how the peptide sequence affects
pathways and interactions accounting for oligomerization in bulk solution. Simulations in aims 2 and 3
will be performed in large boxes containing a seeded fibril. In aim 2, a systematic study will be carried
out to shed light into effects of the fibril surface and the peptide sequence on fibril elongation.
Oligomerization pathways at the fibril surface, i.e., secondary nucleation, will be studied in aim 3. A
comparative study of oligomerization pathways in primary and secondary nucleation will be performed
to determine the interactions enabling the fibril surface to catalyze the aggregation process.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Pathways and interactions accounting for the oligomerization of amyloid peptides
-
批准号:10580438
-
项目类别:
-
资助金额:$47.43万
-
财政年份:2022
-
负责人:Cristiano Luis Dias
-
依托单位:
海外基金